Amryt announces an update regarding the patents for its product Mycapssa. The USPTO has issued to Amryt US Patent No. 11,510,963, with claims related to the Mycapssa product. This patent will expire in February 2036. With the addition of this patent, Amryt has ten Orange Book-listed patents for Mycapssa with patent protection through December 2040. Dr Joe Wiley, CEO of Amryt Pharma, commented: "We are always working to develop and extend our IP portfolio and today’s news further illustrates the robust IP protection enjoyed by Mycapssa."
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMYT: